Soffinova Partners

Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35 years, the firm has backed nearly 500 companies at different stages of development pure creations, spin-offs, as well as turnaround situations and worked alongside Europe key entrepreneurs in the technology, life sciences and cleantech sectors. With 1.1 billion of funds under management, Sofinnova Partners experienced team and hands-on approach in building portfolio companies through to exit have created market leaders, from landmark historical investments including Genentech, Actelion and Vistaprint to more recent successes such as CoreValve, Novexel and Fovea. With a global mindset, the firm has a sister organization in San Francisco, California.
JA

Joe Anderson

Partner

Joseph Anderson

Partner, Crossover Fund

Guillaume Baxter

Principal, Industrial Biotechnology Funds

Maina Bhaman

Partner, Capital Funds

CB

Christophe Blanche

Director of Administration and Finance

Josko Bobanovic

Partner, Industrial Biotechnology Funds

Tom Burt

Partner, Crossover Fund

CC

Claire Catherinet

Analyst, Crossover Fund

AC

Anouck Champsaur

Analyst, Industrial Biotechnology Funds

CD

Cecile Dupont

Senior Associate, Program Director - Mdstart Fund

Adam Evertts

Associate

Lucia Faccio

Partner, Sofinnova Telethon Fund

MG

Marion Gasperment

Associate, Program Manager- Mdstart Fund

AG

Anta Gkelou

Principal, Capital Funds

Lukas Guenther

Partner, Mdstart Fund

Gérard Hascoët

Venture Partner

KH

Kuang He

Analyst, Crossover Fund

Kinam Hong

Partner, Crossover Fund

AJ

Ankeet Jethwa

Associate, Capital Funds

EK

Edward Kliphuis

Partner

Michael Krel

Partner, Industrial Biotechnology Funds

Denis Lucquin

Partner and Senior Advisor

Cedric Moreau

Partner, Crossover Fund

Anne Osdoit

Partner, Mdstart Fund

Antoine Papiernik

Managing Partner and Chairman

Paola Pozzi

Partner, Sofinnova Telethon Fund

HR

Henrijette Richter

Managing Partner

Tiziana Rossetti

Associate, Sofinnova Telethon Fund

Monique Saulnier

Managing Partner and COO

Graziano Seghezzi

Managing Partner

Jacques Theurillat

Partner, Crossover Fund

ST

Simon Turner

Partner

Zhizhong (Joel) Yao

Principal, Capital Funds

282 past transactions

Inside Secure

Series B in 2007
Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

AgroSavfe

Series C in 2019
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Comet Biorefining, Inc.

Venture Round in 2015
Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

EnvoyWorldWide

Series B in 2002
EnvoyWorldWide, Inc. provides enterprise notification and message delivery services. Its notification services for business continuity facilitates personalized, interactive voice and text broadcasts, landline phones, faxes, email, pagers, SMS and WAP phones, PDAs, BlackBerrys, and other wireless devices. The company was formerly known as MessageBlaster.com and changed its name to EnvoyWorldWide, Inc. in September, 2000. The company was founded in 1998 and is headquartered in Bedford, Massachusetts.

LimFlow SA

Series C in 2018
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

myTomorrows

Venture Round in 2017
myTomorrows provides physicians and patients that are excluded from clinical trials access to innovative drugs in development. We focus on disease areas with high unmet needs; oncology, neurology, psychiatry and rare diseases. myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development.

myTomorrows

Venture Round in 2014
myTomorrows provides physicians and patients that are excluded from clinical trials access to innovative drugs in development. We focus on disease areas with high unmet needs; oncology, neurology, psychiatry and rare diseases. myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development.

CelluComp

Venture Round in 2016
CelluComp is a dynamic new material science company based in Scotland that develops high performance products based on sustainable resources. At CelluComp we believe in the possibilities offered by materials produced from non-hydrocarbon feed-stocks. Several years of R&D has led to the development of a range of high performance additives suitable for use in a variety of end applications.

HOOKIPA Pharma Inc.

Series B in 2013
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Comet Biorefining, Inc.

Venture Round in 2019
Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

CrestaTech

Series A in 2008
CrestaTech is developer of cloud-based technologies and services for the smart television sector. CrestaTech’s programmable broadband receivers, all-in-one PCs, notebooks and tablets can support global TV standards with their single reference design. Each device platform is highly programmable with a software-based, multi-standard demodulation capability and flexible front-end interface that allows for the reception and digitization of any global TV signal. CrestatTech’s XC5000 Smart Tuner (TM) ICs are the world’s most highly integrated, high-performance analog and digital silicon TV tuners for flat panel televisions on the market today. With on-board DSP filters, only Xceive ICs provide can service major global analog and digital broadcast television standards. CrestaTech is based in Santa Clara, United States.

PinCell s.r.l.

Seed Round in 2020
PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.
Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

Catamaran Bio

Series A in 2020
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Rgenix, Inc.

Series C in 2018
Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Revolt Technology

Series A in 2005
ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

Sensitive Object

Series A in 2004
Sensitive Object SA develops electronic products for the touch screen, consumer electronics and computing, outdoor interactive, white good, access control, home automation, health care, industrial control, and interactive digital advertising applications. Its products include touch screens, peripherals, and control panels. Sensitive Object SA was founded in 2003 and is based in Boulogne Billancourt, France. It has operations in Paris, France and Singapore, Singapore.

Movetis

Series A in 2007
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Biosyntia

Series A in 2018
Biosyntia ApS operates as a biotechnology company that develops biocatalysts for the fermentation of fine chemicals. The company was incorporated in 2012 and is based in Hørsholm, Denmark.

NuCana BioMed

Series A in 2011
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

MXP4

Series A in 2007
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Streamezzo

Series C in 2007
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

MISSION Therapeutics

Series C in 2016
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

GlycoVaxyn

Series A in 2007
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

Cobion

Venture Round in 2002
Cobion is a text and imaging analysis company. It was founded by Rene Seeber.

Auris Medical

Series C in 2013
They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance. Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Inventiva Pharma

Post in 2019
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

TAK imaging

Series C in 2005
TAK imaging provides imaging processors and SoCs for the printing solutions market. The company offers products, including TAK S1 and TAK S1R, which are system-on-chips (SOC) silicon products for photo-printing; and TAKPRO-800, a single chip SOC for host-based, color laser printer applications.

HighLife SAS

Series B in 2019
HighLife SAS, a medtech company, develops novel transcatheter mitral valve replacement system for treating patients suffering from mitral regurgitation. It focuses on providing a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded in 2010 and is based in Paris, France with an additional office in Irvine, California.

AblaCare

Series A in 2019
AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience. AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is done transvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF.

BioAmber

Series C in 2012
BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture.

NOXXON Pharma AG

Series C in 2007
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

MXP4

Series B in 2009
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.

Asceneuron SA

Series A in 2015
Asceneuron SA is a biotechnology company that discovers and develops therapeutics for neurodegenerative disorders with unmet medical needs. It offers therapeutics for the treatment of progressive supranuclear palsy, orphan tauopathies, and Alzheimer’s and Parkinson’s diseases. The company was founded in 2012 and is based in Lausanne, Switzerland. Asceneuron SA operates as a subsidiary of Merck KGaA.

blueKiwi software

Series B in 2009
blueKiwi Software SA provides enterprise social software for financial firms, high-tech, and professional services agencies. It offers blueKiwi 2009, an enterprise social software for people-centric organizations to create social networks and collaborative environments with partners, customers, and colleagues; and blueKiwi Pro, a social software for small and medium businesses. The company also provides strategic consulting and technical services. It has operations in France and the United Kingdom.

EnvoyWorldWide

Series C in 2002
EnvoyWorldWide, Inc. provides enterprise notification and message delivery services. Its notification services for business continuity facilitates personalized, interactive voice and text broadcasts, landline phones, faxes, email, pagers, SMS and WAP phones, PDAs, BlackBerrys, and other wireless devices. The company was formerly known as MessageBlaster.com and changed its name to EnvoyWorldWide, Inc. in September, 2000. The company was founded in 1998 and is headquartered in Bedford, Massachusetts.

Microphyt

Venture Round in 2019
Microphyt SPAS produces and sells microalgae and other photosynthetic micro-organisms for beauty care and food complement, food, health, and energy markets. The company was incorporated in 2007 and is based in Baillargues, France.

Oxxius

Series B in 2006
Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

Avaki

Series A in 2003
AVAKI provides grid solutions which enable organizations not only to manage but to leverage the explosion in data and applications, within and across enterprises. A grid is a heterogeneous network which appears and functions as one large operating environment. AVAKI grid solutions can be broken down conceptually into two major categories: compute grids and data grids. AVAKI 2.0 delivers the functionality of each, as well as integrated solutions. Any or all aspects of the software can be implemented, depending on an organization's needs.

CorVent Medical

Seed Round in 2020
CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the CorVent™ Single-Use Ventilator, was designed in partnership with Design Catapult, an industrial design firm recognized for their rapid ideation of medical and commercial products. The ventilator is currently pending Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) for ventilators, tubing connectors and accessories, which authorizes its use for the duration of the U.S. Health and Human Services COVID-19 public health emergency declaration.

Aledia SA

Series C in 2018
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

ProQR Therapeutics N.V.

Seed Round in 2013
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Bee Ware

Series A in 2005
Provide a web application filtering, authentication and intrustion prevention systems.

Neosens

Series B in 2009
Neosens SA engages in the design and development of sensor solutions and technologies to monitor and control water and industrial liquids. It offers sensors that monitor the presence of dissolved oxygen in liquid environments; and fouling systems for continuous fouling monitoring in liquid environments. The company’s solutions are used in various water and environmental applications, including cooling systems, heat exchangers, potable water, ultra-pure waters, and industrial boilers, as well as in food and beverage, pharmaceutical, pulp and paper, oil, gas, and petrochemical industries. The company was founded in 2001 and is based in Labege, France.

Aledia SA

Series A in 2013
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

Nitrome Biosciences, Inc.

Series A in 2021
Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Diatos

Series D in 2007
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

ReCor Medical

Series D in 2015
ReCor Medical has developed a unique therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The PARADISE® technology (Percutaneous Renal Denervation System) includes a 6 French catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure.

Gecko Biomedical

Series A in 2016
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.

Crescendo Biologics

Series A in 2014
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Synthace Limited

Series C in 2021
Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

HighLife SAS

Series A in 2017
HighLife SAS, a medtech company, develops novel transcatheter mitral valve replacement system for treating patients suffering from mitral regurgitation. It focuses on providing a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded in 2010 and is based in Paris, France with an additional office in Irvine, California.

Enea Qosmos

Series B in 2006
Qosmos provides software and hardware platforms that identify and extract information traveling through networks. The company's network intelligence technology is designed for use across a wide range of applications such as lawful interception, network protection, data retention, regulatory compliance, and content-based billing.

Tak’asic

Series C in 2004
TAK'ASIC is an innovator in dedicated imaging processors and solutions.

DBV Technologies S.A.

Series B in 2009
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Protera Biosciences, Inc.

Series A in 2020
Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

Creabilis

Series B in 2011
Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

Streamezzo

Series B in 2006
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

Sefas Innovation

Venture Round in 2005
Sefas Innovation was founded in 1991 and has been providing collaborative document composition & production software to Fortune 500 companies for over 15 years. Sefas’ corporate headquarters is in Paris, France, which, along with its UK and US offices, supports over 80 Sefas staff worldwide. Sefas’ Open Print software suite is used by financial services, banking, insurance, utilities, telecoms and public sector organisations for the design, composition and production of B2C documents. These are often complex documents with multiple sources of data; Open Print is unique in its ability to integrate the data from these multiple sources to provide personalized and relevant communications. Increasingly Open Print is being used to redesign mission critical documents so that they can also communicate the latest marketing campaigns and so generate new revenue. The Sefas UK office is based in Bristol and was first opened in 1999. Sefas’ UK clients include Nationwide, EDS Credit Services (Abbey National), HBOS, Inland Revenue, Department of Work & Pensions, Royal & Sun Alliance, RR Donnelley, Bank of Tokyo, DST International and British Telecom who have been using Open Print since (2000).

mydeco

Series A in 2008
Curated collection of designer furniture and home accessories from boutiques in Europe

Inotrem S.A

Series B in 2019
Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

BoostWorks

Series A in 1998
Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

DBV Technologies S.A.

Series C in 2011
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

HotSpot Therapeutics

Seed Round in 2017
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

EnobraQ

Seed Round in 2018
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

ObsEva

Series B in 2015
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2α, or PGF2α receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

IOmx Therapeutics AG

Series B in 2021
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Cotherix

Series C in 2003
Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.
Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

MetGen Oy

Series A in 2013
MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification. MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.

Wyplay

Series A in 2006
WYplay SAS develops digital TV software solutions. The company provides television and home media connected platforms for markets in North America. It offers software licensing to turnkey products, media center consumer electronic (CE) devices, full-HD IPTV boxes, DVB set top boxes, connected televisions, and in-home HD multimedia-HDD products. The company also offers media management, home networking, and connectivity products, as well as connected digital media player, digital media server, CD/DVD optical drive, browser, and analog acquisition components. WYplay SAS was founded in 2006 and is based in Allauch, France.

Inventiva Pharma

Post in 2018
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

MISSION Therapeutics

Series A in 2011
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Erydel

Series B in 2018
EryDel S.p.A. engages in the production and commercialization of drug delivery based on the use of autologous erythrocytes. The company provides medical devices which includes red cell loader, and erykit. The company was founded in 2007 and is based in Urbino, Italy.

RefleXion Medical

Series B in 2016
RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

Crescendo Biologics

Seed Round in 2009
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Laszlo Systems

Series C in 2008
Laszlo Systems provides leading user experience solutions delivering interoperability across applications optimized for mobile and web-enabled devices. Laszlo's web and mobile solutions provide seamless connectivity to multiple backend systems and cloud services while delivering unified user interfaces to dynamically access and share data across applications such as email, contacts, calendar, voice mail. Users can connect to their contacts and social networks, manage a consolidated single list of all their messages (emails, SMS, voice mails, Facebook messages), consume and share media across devices and maintain an aggregated calendar via an intuitive Web interface on their desktops, or straight from their mobile devices and tablets. With Laszlo's solutions, service providers can offer a truly engaging and differentiated experience for integrated communications, messaging and social networking services.

blueKiwi software

Series A in 2007
blueKiwi Software SA provides enterprise social software for financial firms, high-tech, and professional services agencies. It offers blueKiwi 2009, an enterprise social software for people-centric organizations to create social networks and collaborative environments with partners, customers, and colleagues; and blueKiwi Pro, a social software for small and medium businesses. The company also provides strategic consulting and technical services. It has operations in France and the United Kingdom.

Protera Biosciences, Inc.

Series A in 2021
Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

HotSpot Therapeutics

Series A in 2018
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Odoo SA

Series A in 2010
Odoo SA develops and installs a suite of open source business application that help the client grow business. The company offers applications to boost sales that include customer relationship management, point of sales, quote builder, mass mailing, survey, events, community builder, lead automation, and live chat; applications to build Websites that include CMS, e-Commerce, blogs, and forum; and application to run operations that include project management, billing, accounting, warehouse management, manufacturing, and procurements. Its software is available online or on-premise. Odoo SA was formerly known as OpenERP SA. The company was founded in 2005 and is based in Ramillies, Belgium.

Genespire

Series A in 2020
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.

RefleXion Medical

Series C in 2018
RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

NodThera Limited

Series A in 2018
NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Endotis

Series A in 2005
Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Micropep Technologies

Series A in 2018
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

Crescendo Biologics

Series A in 2013
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Blyk

Series A in 2006
Blyk is a messaging media that works with mobile operators to link young people with brands and other stuff they like. Blyk launched its innovative mobile service in he UK in 2007, and quickly became known as a leader in mobile advertising, audience engagement and for its ability to drive unprecedented response rates and return on investment for advertisers. Blyk pioneered the use of interactive text and multi-media messaging as an advertising format, leveraging the most predominant, everyday behaviour of young people (sending and receiving messages on their phones) and enabling young people to communicate with brands in the same way they do with everyone else. Blyk is a private company, with offices in Helsinki, London, Amsterdam and Delhi. It’s current strategic partners include Orange and Vodafone. www.blyk.com

DBV Technologies S.A.

Venture Round in 2006
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

CoreValve

Series C in 2007
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Rgenix, Inc.

Series B in 2016
Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Revolt Technology

Series B in 2009
ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

Ablynx

Series B in 2004
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Sitryx Therapeutics

Series A in 2018
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

Mainstay Medical

Post in 2018
Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

DNA Script SAS

Seed Round in 2016
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Inside Secure

Series C in 2008
Mobile security and secure transaction offerings to protect critical assets including connected devices, content, services and transactions.

Intrinsa

Series B in 2003
Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

Creabilis

Series A in 2008
Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

DMC Biotechnologies, Inc.

Series A in 2019
DMC Biotechnologies, Inc., a biotechnology company, develops bio-based products using microbial fermentation technology. The company's technology for engineering of microbial hosts enables the production of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. It develops and deploys Dynamic Metabolic Control technology that reduces the cost and development timeline from discovery to commercial performance. DMC Biotechnologies, Inc. was founded in 2017 and is based in Boulder, Colorado.

Odoo SA

Series B in 2014
Odoo SA develops and installs a suite of open source business application that help the client grow business. The company offers applications to boost sales that include customer relationship management, point of sales, quote builder, mass mailing, survey, events, community builder, lead automation, and live chat; applications to build Websites that include CMS, e-Commerce, blogs, and forum; and application to run operations that include project management, billing, accounting, warehouse management, manufacturing, and procurements. Its software is available online or on-premise. Odoo SA was formerly known as OpenERP SA. The company was founded in 2005 and is based in Ramillies, Belgium.

VoluBill

Series C in 2005
VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.

Pixium Vision SA

Series A in 2013
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

TAK imaging

Series C in 2008
TAK imaging provides imaging processors and SoCs for the printing solutions market. The company offers products, including TAK S1 and TAK S1R, which are system-on-chips (SOC) silicon products for photo-printing; and TAKPRO-800, a single chip SOC for host-based, color laser printer applications.

RefleXion Medical

Series A in 2014
RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

Intrinsa

Venture Round in 2002
Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

GenSight Biologics

Post in 2019
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Lectus Therapeutics

Series A in 2006
Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.

Innate Pharma

Series A in 2000
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Filao

Venture Round in 2008
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Twenga

Series A in 2015
Twenga provides advanced traffic acquisition solutions for online advertising marketplaces. It helps advertisers to improve performance and the automation of their advertising investments. Twenga employs over 120 people in France, Germany, and England and has over 4000 clients in 15 different countries. Twenga was launched by Bastien Duclaux and Cedric Anes in September 2006 and is based in London, United Kingdom.

CoreValve

Venture Round in 2006
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Neosens

Venture Round in 2008
Neosens SA engages in the design and development of sensor solutions and technologies to monitor and control water and industrial liquids. It offers sensors that monitor the presence of dissolved oxygen in liquid environments; and fouling systems for continuous fouling monitoring in liquid environments. The company’s solutions are used in various water and environmental applications, including cooling systems, heat exchangers, potable water, ultra-pure waters, and industrial boilers, as well as in food and beverage, pharmaceutical, pulp and paper, oil, gas, and petrochemical industries. The company was founded in 2001 and is based in Labege, France.

Domain Therapeutics SA

Series B in 2004
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Alia Therapeutics

Seed Round in 2021
Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.

Myricx Pharma Ltd

Seed Round in 2020
Myricx Pharma Ltd provides drug discovery services that develops proprietary inhibitors of human N-myristoyltransferases. It offers myristoylation, a lipid modification that includes cancer, inflammatory conditions, epilepsy, and Alzheimer’s disease solutions. The company was incorporated in 2019 and is based in Stevenage, United Kingdom.
Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

HOOKIPA Pharma Inc.

Series A in 2011
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Oxxius

Series A in 2004
Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

Ingenium Pharmaceuticals AG

Series B in 2000
Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Aledia SA

Series B in 2015
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.

EnginZyme AB

Series A in 2020
EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating. The company is driven by a mission to make biocatalysis the first choice for chemical process designers worldwide.

Ascendis Pharma

Series A in 2007
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

Omthera Pharmaceuticals

Series A in 2010
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Intrinsa

Series C in 2004
Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

Addex Therapeutics

Series A in 2002
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

CelluComp

Seed Round in 2013
CelluComp is a dynamic new material science company based in Scotland that develops high performance products based on sustainable resources. At CelluComp we believe in the possibilities offered by materials produced from non-hydrocarbon feed-stocks. Several years of R&D has led to the development of a range of high performance additives suitable for use in a variety of end applications.

Stentys

Seed Round in 2007
STENTYS S.A., a medical technology company, develops solutions for treating patients with acute myocardial infarction and other coronary disease in Europe, the Middle East, Latin and South America, and South East Asia. Its product portfolio consists of Xposition S, a sirolimus-eluting self-apposing coronary stent system; Serpentis, a sirolimus eluting stent with a bioabsorbable polymer; MiStent SES, a sirolimus eluting absorbable polymer coronary stent system; and STENTYS AC, an aspiration catheter. The company serves interventional cardiologists. STENTYS S.A. was founded in 2006 and is based in Paris, France.

DNA Script SAS

Series B in 2019
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Ablynx

Series C in 2006
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

IntraWorlds

Seed Round in 2007
PeoplePath provides cloud-based platforms designed to engage and manage relationships with candidates, current and former employees. Conenza and IntraWorlds started out as two companies on two continents with two cultures. When the companies merged in 2020, they became one composite whole that celebrates their unique talents and traits. The company's focus is on tapping its team’s creativity, intellect, and experience to build innovative solutions that delight their customers and community members.

Gecko Biomedical

Series C in 2021
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.

Tak’asic

Series B in 2002
TAK'ASIC is an innovator in dedicated imaging processors and solutions.

Synthace Limited

Venture Round in 2015
Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Domain Therapeutics SA

Series A in 2002
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Meiogenix SAS

Series A in 2021
Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

MastOR SAS

Venture Round in 2023
MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Varioptic

Series B in 2004
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

Borea Therapeutics

Seed Round in 2021
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Addex Therapeutics

Series B in 2004
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

ABIONYX Pharma SA

Series A in 2005
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

MastOR SAS

Series A in 2022
MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Biolipox

Series B in 2003
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Protera Biosciences, Inc.

Series A in 2021
Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed. Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.

Micropep Technologies

Series A in 2021
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

ProQR Therapeutics N.V.

Series A in 2014
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Infra Worlds

Series A in 2004
InfraWorlds is an innovative French startup specializing in embedded Java technologies and solutions for wireless phones. Its technological competencies, coupled with unrivalled graphic creativity, have earned the company a solid reputation among the main players in this booming sector. Built around a team of dedicated professionals, which is soon to be expanded, InfraWorlds is today consolidating its lead in the fast-growing global wireless entertainment market.

Varioptic

Series C in 2006
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

Domain Therapeutics SA

Series C in 2006
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

ENYO Pharma

Series A in 2016
Drug discovery inspired by viruses

Rgenix, Inc.

Series D in 2022
Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Biosyntia

Series B in 2022
Biosyntia ApS operates as a biotechnology company that develops biocatalysts for the fermentation of fine chemicals. The company was incorporated in 2012 and is based in Hørsholm, Denmark.

AAVantgarde Bio

Seed Round in 2021
AAVantgarde Bio is developing gene therapies for inherited retinal disorders.

LimFlow SA

Series D in 2022
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

Shockwave Medical

Series D in 2018
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

AFYREN

Venture Round in 2019
AFYREN SAS provides microbiology and bioprocess engineering services to valorize nonfood biomass into bioenergy and green chemistry. It offers services in the areas of methanogen potential measurements; laboratory analysis; tailor-maid research and development for valorization of wastes and organic effluents; and methanation unit feasibility studies in microbiology, chemistry, and bioprocesses sectors. The company serves pharmaceutical, cosmetic, green chemistry, and biopolymer sector. AFYREN SAS was founded in 2012 and is based in Saint-Beauzire, France.

Esmertec AG

Venture Round in 2002
Esmertec is one of the leading independent software companies focusing on Java™ solutions and technologies for mass-market devices such as mobile multimedia phones, personal digital assistants and home multimedia systems. Their Java device platforms enable major terminal manufacturers, operators and content providers worldwide to deliver wide ranges of customised multimedia services to large groups of consumer audiences.

Micropep Technologies

Series A in 2022
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.

Sequoia Pharmaceuticals

Series B in 2005
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Pi-Cardia

Venture Round in 2020
Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

SafeHeal

Venture Round in 2022
SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) and of the iLab grant program, which foster talent and bring out future champions of the French economy. SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition. Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people.

Sphere Fluidics

Venture Round in 2021
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

ASSIA

Series D in 2010
ASSIA, Inc provides broadband and Wi-Fi performance monitoring, management and optimization software to internet service providers (ISP), communications regulators, and wholesalers so they can improve customer quality of experience and satisfaction, reduce costs through operational efficiencies and increase revenues with new multi-media services.

ABIONYX Pharma SA

Series C in 2010
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Comet Biorefining, Inc.

Venture Round in 2017
Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

ABIONYX Pharma SA

Series B in 2006
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Pixium Vision SA

Post in 2020
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Artios Pharma

Series C in 2021
Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Sequoia Pharmaceuticals

Series C in 2007
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Comet Biorefining, Inc.

Series C in 2021
Comet Biorefining, Inc. develops ingredients or syrup blends, plant dietary fibers, dextrose, and animal Nutrition products. The company provides biomass conversion and pretreatment services. The company offers process development, process technology, engineering, business development, project development, and consulting services. Comet Biorefining, Inc. is based in London, Canada.

CinCor Pharma

Series B in 2021
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

BioSpace

Series B in 2000
BioSpace, Inc. operates an online community for industry news and careers for life science professionals. The company operates BioSpace.com, which provides an online job board, daily biotech news feeds, and community features that connect recruiters, job seekers, and life science professionals. Its community offers recruitment and job seeking opportunities for professionals; and accelerates communication and discovery among business and scientific leaders. The company also provides career events for life science recruiting professionals in the United States and Canada. It serves professionals in biotechnology, pharmaceuticals, medical device, diagnostic, clinical research, academic, and biomedical industries. The company is based in Englewood, Colorado with an additional office in San Francisco, California. BioSpace, Inc. is a former subsidiary of DHI Group, Inc.

Inventiva Pharma

Post in 2020
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Gecko Biomedical

Series B in 2019
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.

Noema Pharma

Series A in 2020
Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Biolipox

Series C in 2005
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Redx Pharma Plc

Post in 2020
Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS. Redx Pharma has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

Purple Labs

Series A in 2007
Purple Labs SA develops mobile Linux software solutions for RTOS and Linux-based mobile devices. It offers The Mobile Linux Platform, a software suite for developing mobile feature phones; and Application suite, a mobile application suite for 3G feature phones, as well as browser and messaging applications for phone manufacturers and customers. The company also provides Purple Magic, a 3G Linux feature phone, which provides video telephony, music playback, high-speed Internet browsing, and video streaming. In addition, it offers application integration and development, Linux support package customization, hardware design and support, and product industrialization services. The company was founded in 2001 and is headquartered in Le Bourget du Lac, France with additional offices in France, the United Kingdom, the United States, China, South Korea, Taiwan, and Hong Kong. As of April 20, 2009, Purple Labs SA operates as a subsidiary of Myriad Group AG.

MetGen Oy

Venture Round in 2013
MetGen develops and produces enzymes tailored to industrial customer needs. MetZymes are enzymes belonging to the class of multicopper oxidases. These enzymes are involved in several oxidative functions and particularly in delignification. MetGen have created biological enzymes that can be added into the pulp mix to separate wood fibres more effectively before the thermo-mechanical pulping stage, radically improving the energy efficiency of the whole pulp-making process.

MedDay

Series A in 2013
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.

QuesCom

Venture Round in 2010
QuesCom S.A. designs and manufactures Internet telecommunication systems. The company provides business communication management portal, GSM gateway, SIM servers, and mobile call servers. It partners with Aastra, Alcatel, Avaya Inc. & Cisco. QuesCom S.A. was founded in 1999 and is headquartered in Sophia Antipolis, France.

Sensitive Object

Series B in 2009
Sensitive Object SA develops electronic products for the touch screen, consumer electronics and computing, outdoor interactive, white good, access control, home automation, health care, industrial control, and interactive digital advertising applications. Its products include touch screens, peripherals, and control panels. Sensitive Object SA was founded in 2003 and is based in Boulogne Billancourt, France. It has operations in Paris, France and Singapore, Singapore.

CorWave SA

Series B in 2016
The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action of the native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system.

Innate Pharma

Series B in 2002
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

GlycoVaxyn

Seed Round in 2006
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

Fovea Pharmaceuticals

Series A in 2005
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Intrinsa

Series D in 2004
Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.

PregLem

Series A in 2007
PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.

AFYX Therapeutics A/S

Debt Financing in 2019
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

PregLem

Series B in 2007
PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.

Delinia, Inc.

Series A in 2016
Delinia, Inc., a biotechnology company, focuses on developing novel therapeutics for the treatment of autoimmune diseases. Its lead program is a molecule that potentiates and expands regulatory T cells (Tregs), which are critical to maintaining self-tolerance and immune system homeostasis. The company was incorporated in 2014 and is based in San Francisco, California. Delinia, Inc. As of February 3, 2017, Delinia, Inc. operates as a subsidiary of Celgene Corporation.

Entourage Medical Technologies

Venture Round in 2013
A stealth company that has not yet released what it focuses on.

GenSight Biologics

Post in 2020
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

HOOKIPA Pharma Inc.

Series C in 2017
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

CorWave SA

Series C in 2021
The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action of the native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system.
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Green Biologics

Series C in 2015
Green Biologics is a revenue generating industrial biotech company based in Oxfordshire aiming to become the world's leading supplier of advanced fermentation technologies for conversion of biomass to renewable fuels and chemicals.

Zyl

Venture Round in 2017
Zyl develops an application to gather and share photos with friends and family. The company offers a mobile application that allows users to create events and invite friends to their timeline; view and share their event's timeline; and synchronize pictures. Zyl was formerly known as Comet and changed its name to Zyl in November 2017. The company was incorporated in 2015 and is based in Saint-Maur-des-Fossés, France.

Innate Pharma

Series C in 2004
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Mainstay Medical

Series A in 2010
Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Laszlo Systems

Series B in 2005
Laszlo Systems provides leading user experience solutions delivering interoperability across applications optimized for mobile and web-enabled devices. Laszlo's web and mobile solutions provide seamless connectivity to multiple backend systems and cloud services while delivering unified user interfaces to dynamically access and share data across applications such as email, contacts, calendar, voice mail. Users can connect to their contacts and social networks, manage a consolidated single list of all their messages (emails, SMS, voice mails, Facebook messages), consume and share media across devices and maintain an aggregated calendar via an intuitive Web interface on their desktops, or straight from their mobile devices and tablets. With Laszlo's solutions, service providers can offer a truly engaging and differentiated experience for integrated communications, messaging and social networking services.

Avantium N.V.

Series G in 2014
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

Accent

Venture Round in 2006
Accent is an ISO 9001:2008 certified provider of semiconductor integration of metering technologies and communication and with renowned investors such as Sofinnova Partners (France) and Cadence. Accent provides products and solutions targeted vertical markets including Smart Grid and Clean Tech. It also offers areas such as wireless, analog mixed signal, and low power—and pre-integrated platforms provide rapid time to market to meet critical product cost and performance requirements whilst at low development cost.

GlycoVaxyn

Series B in 2009
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

DNA Script SAS

Series A in 2017
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Varioptic

Series A in 2003
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.

HOOKIPA Pharma Inc.

Series B in 2016
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Inotrem S.A

Series A in 2014
Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Filao

Venture Round in 2005
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Enea Qosmos

Series C in 2008
Qosmos provides software and hardware platforms that identify and extract information traveling through networks. The company's network intelligence technology is designed for use across a wide range of applications such as lawful interception, network protection, data retention, regulatory compliance, and content-based billing.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

Shockwave Medical

Series B in 2015
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Ocera Therapeutics

Series C in 2008
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Green Biologics

Series B in 2013
Green Biologics is a revenue generating industrial biotech company based in Oxfordshire aiming to become the world's leading supplier of advanced fermentation technologies for conversion of biomass to renewable fuels and chemicals.

CinCor Pharma

Series A in 2019
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

NOXXON Pharma AG

Series D in 2010
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

Mobile Digital Media

Venture Round in 2008
A company that builds software that runs games and other applications on mobile devices.

UPEK

Series A in 2004
UPEK, Inc., the global leader in biometric fingerprint security solutions, offers integrated end-to-end solutions including comprehensive design & integration services to the world’s leading consumer and industrial products companies. UPEK solutions enable the strongest fingerprint authentication security available and effortless user convenience. UPEK security solutions are easy to deploy and integrate with existing infrastructure and network architectures. UPEK biometric security products enable a wide range of applications including password replacement for PCs and applications, centralized management for corporate network security, secure mobile transactions, protection of portable data, identity verification for government and military applications, and physical access control. UPEK has been pioneering biometric fingerprint technology since 1996 and shipping product in volume since 1999. UPEK is headquartered near Berkeley, California with offices in Prague, Singapore, Taipei and Tokyo.

BoostWorks

Series B in 1999
Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

GenSight Biologics

Post in 2019
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Enthera S.r.l.

Series A in 2020
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy. Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio.

Enthera S.r.l.

Seed Round in 2018
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy. Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio.

Bee Ware

Series B in 2010
Provide a web application filtering, authentication and intrustion prevention systems.

Synthace Limited

Seed Round in 2013
Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Mainstay Medical

Private Equity Round in 2021
Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Ablynx

Series A in 2002
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Omthera Pharmaceuticals

Series B in 2011
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Epsilen Bio Srl

Seed Round in 2020
Epsilen Bio is developing a transformative therapy known as Epigenetic Silencing to treat human diseases. Epsilen Bio's mission is to develop therapies for patients affected by underserved medical conditions, through stable genomic epigenetic silencing of genes involved in pathological processes. The company was founded in December 2019 and based in Milan, Italy.

Crescendo Biologics

Series B in 2018
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

NuCana BioMed

Series B in 2014
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

MISSION Therapeutics

Venture Round in 2020
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

IOmx Therapeutics AG

Series A in 2016
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

Esmertec AG

Series C in 2003
Esmertec is one of the leading independent software companies focusing on Java™ solutions and technologies for mass-market devices such as mobile multimedia phones, personal digital assistants and home multimedia systems. Their Java device platforms enable major terminal manufacturers, operators and content providers worldwide to deliver wide ranges of customised multimedia services to large groups of consumer audiences.

Tak’asic

Series C in 2005
TAK'ASIC is an innovator in dedicated imaging processors and solutions.

VoluBill

Series D in 2007
VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.

Shockwave Medical

Series C in 2016
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

HotSpot Therapeutics

Series B in 2020
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

CrestaTech

Seed Round in 2005
CrestaTech is developer of cloud-based technologies and services for the smart television sector. CrestaTech’s programmable broadband receivers, all-in-one PCs, notebooks and tablets can support global TV standards with their single reference design. Each device platform is highly programmable with a software-based, multi-standard demodulation capability and flexible front-end interface that allows for the reception and digitization of any global TV signal. CrestatTech’s XC5000 Smart Tuner (TM) ICs are the world’s most highly integrated, high-performance analog and digital silicon TV tuners for flat panel televisions on the market today. With on-board DSP filters, only Xceive ICs provide can service major global analog and digital broadcast television standards. CrestaTech is based in Santa Clara, United States.

PhyFlex Networks

Series B in 2002
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Fovea Pharmaceuticals

Series B in 2007
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Abivax

Post in 2019
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.

MD Start

Venture Round in 2016
MD Start SA offers fund placement services to medical device start-up corporations. It has partnerships with Medtronic, Sofinnova Partners, Sorin Group, Versant Ventures, Contract Medical International, and Corscience GmbH & Co. KG. The company, formerly known as Medical Device Accelerator, was founded in 2009 and is based in Lausanne, Switzerland.

Nitrome Biosciences, Inc.

Series A in 2020
Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

NodThera Limited

Series B in 2020
NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Filao

Venture Round in 2005
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Shockwave Medical

Series A in 2014
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

BioAmber

Series A in 2010
BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

SafeHeal

Series A in 2018
SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) and of the iLab grant program, which foster talent and bring out future champions of the French economy. SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition. Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people.

Synthace Limited

Series A in 2017
Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Castle Biosciences

Venture Round in 2018
Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

Addex Therapeutics

Series C in 2006
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Pyrowave Inc.

Series B in 2020
Pyrowave Inc. develops recycling technology solutions based on the use of microwave to convert plastics into liquid products and brings plastics back to the molecular state identical to virgin materials. The company leases machines for recycling plastics; and sells liquid products and other high-value materials generated during processing. It serves municipal clients, and private recyclers and generators. Pyrowave Inc. was incorporated in 2014 and is headquartered in Oakville, Canada.

Streamezzo

Series D in 2009
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

Comet Therapeutics

Series A in 2019
CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.

NuCana BioMed

Series A in 2011
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

Twentyeight-Seven, Inc.

Series A in 2019
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

AgroSavfe

Series B in 2017
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

MISSION Therapeutics

Series B in 2013
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Stentys

Series A in 2008
STENTYS S.A., a medical technology company, develops solutions for treating patients with acute myocardial infarction and other coronary disease in Europe, the Middle East, Latin and South America, and South East Asia. Its product portfolio consists of Xposition S, a sirolimus-eluting self-apposing coronary stent system; Serpentis, a sirolimus eluting stent with a bioabsorbable polymer; MiStent SES, a sirolimus eluting absorbable polymer coronary stent system; and STENTYS AC, an aspiration catheter. The company serves interventional cardiologists. STENTYS S.A. was founded in 2006 and is based in Paris, France.

MedDay

Series B in 2016
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.